Tissue factor (TF) is involved in cancer growth and metastasis, and haemostatic abnormalities are found in most patients with advanced malignancies, including prostate cancer (PC). Because anti-haemostatic agents are increasingly screened for their potential to prolong survival in tumor patients, a detailed characterization of haemostatic markers in selected cancer subtypes and clinical stages is warranted. In this study, we measured preoperative plasma TF antigen in a large cohort of patients with localized PC and correlated its levels with markers of coagulation and platelet activation, prostate-specific antigen (PSA), and his-topathological findings to explore its potential as a prognostic marker in this tumor entity. Out of 140 patients, 19% and 23% had plasma TF antigen levels of <40 pg/ml (low-TF) and >200 pg/ ml (high-TF), respectively, which was substantially higher than in 42 healthy male controls. Patients also had low-grade systemic coagulation activation as evidenced by elevated D-dimer, FI +2, and PAP plasma levels. Furthermore, similar to sP-selectin and sCD40L antigen, flow cytometric analysis of platelet-derived microparticles in plasma revealed significantly increased numbers in high-TF as compared to low-TF patients and controls. Whereas elevated D-dimer was associated with larger and less differentiated tumors, preoperative plasmaTF antigen levels (median [IQR]) were higher in patients with (161 pg/ml [100-236]) than in those without recurrent PC (105 pg/ml [52-182]), as indicated by a serum PSA of >0.1 ng/ml during ambulatory follow-up. In patients with localized PC, preoperative plasma TF antigen levels correlate with platelet activation in vivo and may indicate an increased risk for recurrent disease.
Keywords
Tissue factor/factor VII -
cancer -
microparticles
Footnote: Parts of this work were presented at the 47th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, USA 2005.
References
1
Mackman N.
Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-1022.
2
Belting M,
Ahamed J,
Ruf W.
Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005; 25: 1545-1550.
6
Koomagi R,
Volm M.
Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998; 79: 19-22.
8
Ohta S,
Wada H,
Nakazaki T.
et al. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 2002; 22: 2991-2996.
9
Seitz R,
Rappe N,
Kraus M.
et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 1993; 4: 249-254.
10
Oya M,
Akiyama Y,
Okuyama T.
et al. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001; 31: 388-394.
11
Dirix LY,
Salgado R,
Weytjens R.
et al. Plasma fibrin D-dimer levels correlate with tumor volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-395.
13
Lind SE,
Caprini JA,
Goldshteyn S.
et al. Correlates of thrombin generation in patients with advanced prostate cancer. Thromb Haemost 2003; 89: 185-189.
14
Bogdanov VY,
Balasubramanian V,
Hathcock J.
et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9: 458-462.
18
Sase T,
Wada H,
Kamikura Y.
et al. Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. Thromb Haemost 2004; 92: 132-139.
19
Mohan JS,
Lip GYH,
Wright J.
et al. Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation. Blood Coagul Fibrinolysis 2005; 16: 209-214.
20
Kim HK,
Song KS,
Park YS.
et al. Changes of plasma tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology 2000; 93: 31-36.
21
Han LY,
Landen Jr CN,
Kamat AA.
et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 2006; 24: 755-761.
22
Kohli M,
Fink LM,
Spencer HJ.
et al. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis 2002; 13: 1-5.
25
Bill-Axelson A,
Holmberg L,
Ruutu M.
et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-1984.
26
Kakkar AK,
Levine MN,
Kadziola Z.
et al. Low molecular weight heparin, therapy with Dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
27
Lee AY,
Rickles FR,
Julian JA.
et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129.
28
Combes V,
Dignat-George F,
Mutin M.
et al. A new flow cytometry method of platelet-derived microvesicle quantitation in plasma. Thromb Haemost 1997; 77: 220
30
Caine JC,
Lip GYH,
Stonelake PSS.
et al. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004; 92: 185-190.
32
Fink L,
Holschermann H,
Kwapiszewska G.
et al. Characterization of platelet-specific mRNA by realtime PCR after laser-assisted microdissection. Thromb Haemost. 2003: 749-756.
33
Camera M,
Frigerio M,
Toschi V.
et al. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol 2003; 23: 1690-1696.
35
Muller I,
Klocke A,
Alex M.
et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003; 17: 476-478.
37
Del Conde I,
Shrimpton CN,
Thiagarajan P.
et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
39
Schwertz H,
Tolley ND,
Foulks JM.
et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets. J Exp Med 2006; 203: 2433-2440.
